2006
DOI: 10.1007/s00280-006-0189-6 View full text |Buy / Rent full text
|
|

Abstract: NV06 is well tolerated and can be given safely as an intravenous infusion over 1-2 h at a dose of at least 30 mg/kg.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
1
0
17
1

Year Published

2009
2009
2011
2011

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

0
17
1
Order By: Relevance
“…16,18 The pharmacokinetics, bioavailability, and safety of intravenous (IV) phenoxodiol have been established in previous phase I clinical trials. 19,20 The first use of IV phenoxodiol in ovarian cancer was conducted at our institution. Forty patients with recurrent ovarian, fallopian tube, or primary peritoneal cancers who had failed second-line therapy were treated with 1 of 4 dose levels (1, 3, 10, and 20 mg/kg) of IV phenoxodiol administered on 2 consecutive days per week.…”
mentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 100,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…16,18 The pharmacokinetics, bioavailability, and safety of intravenous (IV) phenoxodiol have been established in previous phase I clinical trials. 19,20 The first use of IV phenoxodiol in ovarian cancer was conducted at our institution. Forty patients with recurrent ovarian, fallopian tube, or primary peritoneal cancers who had failed second-line therapy were treated with 1 of 4 dose levels (1, 3, 10, and 20 mg/kg) of IV phenoxodiol administered on 2 consecutive days per week.…”
mentioning
“…1,2 Phenoxodiol has been referred to as a pan-cancer drug, 3 causing apoptosis in cancer cell lines and murine cancer models via both intrinsic and extrinsic pathways. [4][5][6][7][8][9][10][11][12][13][14] Plasma membrane electron transport (PMET) has been shown to be a target of phenoxodiol in several studies with cancer cell lines.…”
Section: Introductionmentioning
“…It may be capable of re-sensitising platinum-and taxane-resistant ovarian cancer cells in vitro (Kamsteeg et al, 2003;Sapi et al, 2004;Kluger et al, 2007) and appears to have antiangiogenic (Gamble et al, 2006) and anti-inflammatory properties (Widyarini et al, 2001). It has improved bioavailability when compared with genistein (Kelly and Husband, 2003) and low toxicity in clinical trials (Joshua et al, 2003;Choueiri et al, 2006a;de Souza et al, 2006).…”
mentioning